Bioventus Inc. Cash Flow Statement
BVS|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Bioventus Inc. generated $75M in operating cash flow and $72M in free cash flow in FY2025. Free cash flow margin was 12.7% of revenue.
Based on SEC 10-K filings.
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.93 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | $22.7M | -$36.1M | $19.4M | -$158.7M | $6.9M |
| Depreciation & Amortization | $47.0M | $49.6M | $34.9M | $55.4M | $30.3M |
| Operating Cash Flow | $74.7M | $38.8M | $23.0M | -$13.5M | $40.7M |
| Capital Expenditures | $2.6M | $1.0M | $13.5M | $1.5M | $2.3M |
| Free Cash Flow | $72.1M | $37.8M | $9.5M | -$15.0M | $38.4M |
| FCF Margin | 12.7% | 6.6% | 2.2% | -2.9% | 11.3% |